BioSenic puts Phase IIb ALLOB trial on hold

INSIDE INFORMATION Prior efficacy unmatched but excellent safety profile confirmed, timing of ALLOB administration for optimal bone repair to...

Related Keywords

Mont Saint Guibert ,Waals Gewest ,Belgium ,France ,Paris ,France General ,French ,Lieven Huysse ,Neil Hunter Michelle Boxall ,Ghislaine Gasparetto ,International Media Enquiries ,Ib Communications ,Euronext Brussels ,Chief Medical Officer ,Host Disease ,Full Study Population ,Per Protocol ,Chief Executive Officer ,Arsenic Trioxide ,Systemic Sclerosis ,Louvain La Neuve Science Park ,Mesenchymal Stromal Cells ,Graft Versus Host Disease ,Systemic Lupus ,Chief Executive ,French Investor Enquiries ,Brussels Stock Exchange Bios ,Biosenic ,